Back to Search Start Over

Myosteatosis Significantly Predicts Persistent Dyspnea and Mobility Problems in COVID-19 Survivors.

Authors :
De Lorenzo R
Palmisano A
Esposito A
Gnasso C
Nicoletti V
Leone R
Vignale D
Falbo E
Ferrante M
Cilla M
Magnaghi C
Martinenghi S
Vitali G
Molfino A
Rovere-Querini P
Muscaritoli M
Conte C
Source :
Frontiers in nutrition [Front Nutr] 2022 Apr 08; Vol. 9, pp. 846901. Date of Electronic Publication: 2022 Apr 08 (Print Publication: 2022).
Publication Year :
2022

Abstract

Background: Persistent symptoms including dyspnea and functional impairment are common in COVID-19 survivors. Poor muscle quality (myosteatosis) associates with poor short-term outcomes in COVID-19 patients. The aim of this observational study was to assess the relationship between myosteatosis diagnosed during acute COVID-19 and patient-reported outcomes at 6 months after discharge.<br />Methods: Myosteatosis was diagnosed based on CT-derived skeletal muscle radiation attenuation (SM-RA) measured during hospitalization in 97 COVID-19 survivors who had available anthropometric and clinical data upon admission and at the 6-month follow-up after discharge. Dyspnea in daily activities was assessed using the modified Medical Research Council (mMRC) scale for dyspnea. Health-related quality of life was measured using the European quality of life questionnaire three-level version (EQ-5D-3L).<br />Results: Characteristics of patients with (lowest sex- and age-specific tertile of SM-RA) or without myosteatosis during acute COVID-19 were similar. At 6 months, patients with myosteatosis had greater rates of obesity (48.4 vs. 27.7%, p = 0.046), abdominal obesity (80.0 vs. 47.6%, p = 0.003), dyspnea (32.3 vs. 12.5%, p = 0.021) and mobility problems (32.3 vs. 12.5%, p = 0.004). Myosteatosis diagnosed during acute COVID-19 was the only significant predictor of persistent dyspnea (OR 3.19 [95% C.I. 1.04; 9.87], p = 0.043) and mobility problems (OR 3.70 [95% C.I. 1.25; 10.95], p = 0.018) at 6 months at logistic regression adjusted for sex, age, and BMI.<br />Conclusion: Myosteatosis diagnosed during acute COVID-19 significantly predicts persistent dyspnea and mobility problems at 6 months after hospital discharge independent of age, sex, and body mass.<br />Clinical Trial Registration: [www.ClinicalTrials.gov], identifier [NCT04318366].<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 De Lorenzo, Palmisano, Esposito, Gnasso, Nicoletti, Leone, Vignale, Falbo, Ferrante, Cilla, Magnaghi, Martinenghi, Vitali, Molfino, Rovere-Querini, Muscaritoli and Conte.)

Details

Language :
English
ISSN :
2296-861X
Volume :
9
Database :
MEDLINE
Journal :
Frontiers in nutrition
Publication Type :
Academic Journal
Accession number :
35464004
Full Text :
https://doi.org/10.3389/fnut.2022.846901